PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since it is highly deregulated in this disease and it also mediates resistance to anti-HER2 therapies. However, initial stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Serra, V, Scaltriti, M, Prudkin, L, Eichhorn, P J A, Ibrahim, Y H, Chandarlapaty, S, Markman, B, Rodriguez, O, Guzman, M, Rodriguez, S, Gili, M, Russillo, M, Parra, J L, Singh, S, Arribas, J, Rosen, N, Baselga, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107390/
https://www.ncbi.nlm.nih.gov/pubmed/21278786
http://dx.doi.org/10.1038/onc.2010.626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107390/
https://www.ncbi.nlm.nih.gov/pubmed/21278786
http://dx.doi.org/10.1038/onc.2010.626

Ejemplares similares